Wall Street brokerages expect Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) to announce ($0.67) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Zynerba Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.73) and the highest is ($0.61). Zynerba Pharmaceuticals posted earnings per share of ($0.60) during the same quarter last year, which would suggest a negative year over year growth rate of 11.7%. The firm is expected to report its next quarterly earnings report on Monday, March 11th.
On average, analysts expect that Zynerba Pharmaceuticals will report full-year earnings of ($2.87) per share for the current fiscal year, with EPS estimates ranging from ($2.94) to ($2.79). For the next year, analysts expect that the company will post earnings of ($2.43) per share, with EPS estimates ranging from ($2.77) to ($1.84). Zacks Investment Research’s EPS calculations are an average based on a survey of research firms that follow Zynerba Pharmaceuticals.
Zynerba Pharmaceuticals (NASDAQ:ZYNE) last issued its earnings results on Thursday, November 8th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.70) by $0.23.
ZYNE has been the topic of a number of recent research reports. HC Wainwright set a $23.00 target price on shares of Zynerba Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, November 13th. Cantor Fitzgerald set a $21.00 target price on shares of Zynerba Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday. Zacks Investment Research raised shares of Zynerba Pharmaceuticals from a “hold” rating to a “buy” rating and set a $6.00 target price on the stock in a report on Saturday, November 17th. Finally, ValuEngine raised shares of Zynerba Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, August 14th. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $17.75.
Several institutional investors and hedge funds have recently added to or reduced their stakes in ZYNE. Thompson Siegel & Walmsley LLC bought a new stake in shares of Zynerba Pharmaceuticals during the third quarter valued at approximately $157,000. Raymond James & Associates acquired a new position in shares of Zynerba Pharmaceuticals during the second quarter valued at approximately $164,000. GSA Capital Partners LLP acquired a new position in shares of Zynerba Pharmaceuticals during the third quarter valued at approximately $177,000. Zeke Capital Advisors LLC acquired a new position in shares of Zynerba Pharmaceuticals during the third quarter valued at approximately $193,000. Finally, Engineers Gate Manager LP acquired a new position in shares of Zynerba Pharmaceuticals during the second quarter valued at approximately $231,000. 16.50% of the stock is currently owned by institutional investors.
NASDAQ ZYNE traded up $0.03 during trading hours on Monday, reaching $4.80. The company’s stock had a trading volume of 116,277 shares, compared to its average volume of 235,962. Zynerba Pharmaceuticals has a 52 week low of $4.50 and a 52 week high of $14.45.
About Zynerba Pharmaceuticals
Zynerba Pharmaceuticals, Inc operates as a clinical stage specialty pharmaceutical company. The company focuses on developing and commercializing pharmaceutically-produced transdermal cannabinoid treatments for rare or near-rare neuropsychiatric disorders. Its product candidates include ZYN002, which completed Phase II clinical trial for pediatric and adolescent patients with fragile X syndrome, pediatric and adolescent patients with developmental and epileptic encephalopathies, and adult patients with refractory epileptic focal seizures; and ZYN001 that is in Phase I clinical trial to treat Tourette syndrome.
Featured Article: Dollar Cost Averaging
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zynerba Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.